What's Happening?
The Health Innovation Network's (HIN) National Polypharmacy Programme, aimed at addressing problematic polypharmacy in England, has concluded. Launched in 2022, the programme was designed to run for three years and ended in September 2025. During its tenure, the programme trained over 1,300 pharmacists and GPs through Polypharmacy Action Learning Sets, and supported more than 2,000 healthcare professionals in tackling overprescribing. Despite hopes for continued funding or an alternative host to sustain the programme, no such arrangements have been secured. The programme's resources are intended to leave a lasting legacy, encouraging shared decision-making around polypharmacy. Lelly Oboh, clinical care and professional lead for overprescribing at NHS South East London, emphasized the programme's foundational role in reducing overprescribing and enhancing the uptake and quality of Structured Medication Reviews (SMRs).
Why It's Important?
The conclusion of the HIN's National Polypharmacy Programme marks a significant moment for the NHS's efforts to combat overprescribing. The programme's success in training healthcare professionals and developing resources highlights the importance of sustained national investment in addressing polypharmacy. As the population ages, the complexities of polypharmacy increase, making it crucial to equip clinicians with the necessary skills and support for safe deprescribing practices. Without ongoing education and system support, the gains achieved through the programme risk being undermined, potentially affecting patient care and safety. The programme's end could impact the NHS's ability to implement the National Overprescribing Review recommendations fully.
What's Next?
While the programme has ended, discussions continue regarding potential funding or alternative hosting to sustain its efforts. Healthcare professionals are encouraged to join the shared learning network to maintain momentum in addressing polypharmacy. The NHS may need to explore new strategies or partnerships to continue supporting clinicians in safe deprescribing practices. The programme's resources will remain available to aid healthcare professionals in aligning medication use with patient goals, ensuring medicines are used effectively and safely.
Beyond the Headlines
The end of the HIN's programme raises broader questions about the sustainability of healthcare initiatives without long-term funding. It underscores the need for cultural change within the NHS to prioritize safe prescribing practices. The programme's legacy may influence future policy frameworks and guidance, emphasizing the importance of equipping clinicians with the skills and confidence to manage polypharmacy effectively.
